AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|
23.3 C
New York
Thursday, July 30, 2026

Tag: immune system

newssourceFORcompanyinformationcontent1releasesmarket

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")...

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech and Compedica Stock-for-Stock Exchange

CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform

Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program 
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design of its Phase 2/3 IIMPACT (Idiopathic Inflammatory Myopathy Phase 2/3 Adaptive Clinical Trial) trial of Restem-L, the Company’s umbilical-lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). The oral presentation will be delivered at the European Alliance of Associations for Rheumatology's (EULAR) 2025 Congress, to take place June 11-14 in Barcelona, Spain.

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase...

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors.

CancerVax Achieves Major Milestone with Successful Creation of Cell Targeting Nanoparticle

Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells 
Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsImmune system

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers